Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical and radiological remission of disease and to reduce functional limitations and permanent joint damage.
In patients with early rheumatoid arthritis (RA), vitamin D deficiency is associated with more active and severe disease at baseline and is a predictor of disability and radiographic progression, suggests a study.
For rheumatoid arthritis (RA) patients initiating a new treatment, contactless monitoring via a smartphone application cuts down on office visits while keeping up tight control of disease activity, which in turn boosts general well-being, as shown in a study.
Treatment with E6011, a novel cell trafficking inhibitor targeting the fractalkine (FKN)‐CX3CR1 interaction, confers modest benefits in rheumatoid arthritis (RA), according to the results of a phase II trial.
Dehydroepiandrosterone supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.
Ritlecitinib, an oral JAK3/TEC inhibitor, appears to be well tolerated and produce significant improvements disease activity in patients with rheumatoid arthritis, according to the results of a phase II study.
More than half of rheumatoid arthritis (RA) patients achieving low disease activity on long-term methotrexate (MTX) remain flare-free following its withdrawal, as shown in a study. The use of a higher MTX dose to preserve low disease activity is predictive of disease flare after discontinuation.
The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.